Every cycle of ART involves multiple steps, and each occurs at a specific time during a four to six-week period. The following is an overview of the IVF procedure. The procedure begins in the month proceeding the actual ART cycle. An IVF cycle typically includes the following steps or procedures:

• Medications to grow multiple eggs 
• Retrieval of eggs from the ovary or ovaries 
• Insemination of eggs with sperm  
• Culture of any resulting fertilized eggs (embryos) 
• Placement ("transfer") of one or more embryo(s) into the uterus 
• Support of the uterine lining with hormones to permit and sustain pregnancy 

In certain cases, these additional procedures can be employed:

• Intracytoplasmic sperm injection (ICSI) to increase the chance for fertilization 
• Assisted hatching of embryos to potentially increase the chance of embryo attachment ("implantation") 
• Embryo cryopreservation (freezing)

The success of IVF largely depends on growing multiple eggs at once

• Injections of the natural hormones FSH and/or LH (gonadotropins) are used for this purpose
• Additional medications are used to prevent premature ovulation
• An overly vigorous ovarian response can occur, or conversely an inadequate response.

Cycle Preceding ART Cycle

1. Sometimes oral contraceptives are begun.
2. Sometimes a GnRH agonist (e.g. Lupron®) is initiated.
3. Sometimes a mock transfer is performed to identify potential problems in embryo transfer.
4. Occasionally, an IVF cycle starts with a cycle day of the menstrual period without other medications.

ART Cycle

1. Prestimulation treatment 
2. Ovarian stimulation with gonadotropins (e.g. Bravelle®, Menopur®, Follistim®, Repronex®, Gonal-F®, Follistim AQ pen, and/or Gonal-F RFF Pen)
3. Monitoring follicle development with ultrasound and serum hormone levels 
4. Final oocytes maturation and hCG administration (Profasi®, Pregnyl®, Novarel® or Ovidrel®) 
5. Transvaginal oocyte retrieval 
6. Insemination
7. Embryo transfer 
8. Progesterone supplementation 
9. Pregnancy test Early pregnancy follow-up 

Step 1 – Prestimulation Treatment

Initiation of Oral Contraceptives
Some patients will receive oral contraceptives in the cycle prior to the ART cycle. This ensures that GnRH analog therapy will start at the proper time if you have irregular cycles. There is also evidence that oral contraceptives can help prevent ovarian cysts, which sometimes develop during GnRH analog therapy.  Provera® or progesterone may be prescribed for patients who ovulate irregularly or not at all.

Suppression of Ovulation
There are two principle ways that physicians ensure ovulation does not occur before egg retrieval.  One involves pre-treatment of a patient with a GnRH agonist.  The other involves treatment after six or so days of stimulation with a GnRH antagonist.

GnRH Agonist Administration
GnRH agonist (Lupron®):  This medication is taken by injection. There are two forms of the medication: A short acting medication requiring daily injections and a long-acting preparation lasting for 1-3 months.  The primary role of this medication is to prevent a premature LH surge, which could result in the release of eggs before they are ready to be retrieved. Since GnRH-agonists initially cause a release of FSH and LH from the pituitary, they can also be used to start the growth of the follicles or initiate the final stages of egg maturation.

A GnRH agonist might be prescribed sometime after taking oral contraceptive pills. This dose may be reduced when ovarian stimulation is begun. Agonist is often discontinued on the day of hCG (human chorionic gonadotropin) administration.

Some protocols also might begin GnRH agonist sometime after ovulation in the cycle preceding stimulation in the "mid-luteal" protocol, after the start of menses in the "flare" or "micro-flare" protocol.

GnRH-antagonists (ganirelix acetate or cetrorelix acetate) (Antagon®, Cetrotide®):  These are other classes of medications used to prevent premature ovulation.  They are typically administered several days after stimulation and require fewer injections.

Baseline Pelvic Ultrasound
Around the time of your expected period, your physician will perform an ultrasound scan to examine the ovaries. If your physician detects a cyst, they may withhold further therapy until the cysts resolve spontaneously (usually in about a week). Occasionally, cyst aspiration (drainage) is recommended. This is a procedure in which your doctor inserts a fine needle connected to a syringe, guided by ultrasound, into the cyst. They may also perform a blood test (serum estradiol measurement) to confirm that the ovaries are properly suppressed.

Step 2 - Ovarian Stimulation

In general, ovarian stimulation begins after menstrual bleeding starts. Several similar medications may be used to stimulate follicle development: Bravelle®, Repronex®, Lupron®, Gonal-F®, Repronex® Follistim® Follistim AQ pen and Gonal-F RFF Pen. GnRH-antagonists (ganirelix acetate or cetrorelix acetate) (Antagon®, Cetrotide®) are another class of medications used to prevent premature ovulation and, in combination with an antagonist trigger, they may offer protection from severe ovarian hyperstimulation syndrome.  They tend to be used for short periods of time in the late stages of ovarian stimulation.  There are several different types of stimulation protocols.  Although all protocols more-or-less employ the same types of medications, specific protocols may help certain types of patients to have a better response than other types.  It is, however, unrealistic to think that switching from one protocol to another will dramatically change a poorly responding patient to a highly responding patient.

Step 3 - Monitoring of Follicle Development

Follicuar development is monitored with a combination of vaginal ultrasound and hormone measurements (blood tests). These tests are performed frequently during the ART cycle, and the dose of medication might be adjusted in an effort to improve follicular development. The amount of medication prescribed also depends upon the results of the blood tests and ultrasound exams.

Step 4 - Final Oocyte Maturation and hCG Administration

Human chorionic gonadotropin (hCG) (Profasi®, Novarel®, Pregnyl®, Ovidrel®) is a hormonal drug that stimulates the final maturation of the oocytes. Determining the proper day for hCG administration is critical. The time of the injection determines when the egg retrieval will be scheduled.  Some protocols using GnRH antagonists use GnRH agonists to trigger the final maturation of oocytes.

Step 5 - Transvaginal Oocyte Retrieval 

• Eggs are removed from the ovary with a needle under ultrasound guidance.
• Anesthesia is provided to make this comfortable.
• Injury and infection are rare.

Oocyte retrieval is performed about 34-36 hours after hCG has been administered. An anesthesiologist usually administers intravenous medications (sedatives and pain relievers) in order to minimize the discomfort that may occur during the procedure. Most patients sleep through the procedure. A transvaginal ultrasound probe is used to visualize the ovaries and the egg-containing follicles within the ovaries. A long needle, which can be seen on ultrasound, can be guided into each follicle and the contents aspirated. The aspirated material includes follicular fluid, oocytes (eggs) and granulosa (egg-supporting) cells. The physician will collect the oocytes and follicular fluid into a test tube and the embryologist will search the follicular fluid and locate the oocytes using a microscope.

After the retrieval, patients recover from anesthesia where they will be observed while the intravenous medications wear off. It is not uncommon to have some vaginal spotting and lower abdominal discomfort for several days following this procedure. Generally, patients feel completely recovered within 1 to 2 days.

The number of oocytes retrieved is related to the number of ovaries, their accessibility, and the number of follicles that develop in response to stimulation. Ultrasound provides only an approximation of the number of oocytes that one can expect to recover. On the average, 8 to 15 oocytes are retrieved per patient.

 

Step 6 - Semen 

Step 7- Embryology Lab Procedures

After eggs are retrieved, they are transferred to the embryology laboratory where they are kept in conditions that support their needs and growth. The embryos are placed in small dishes or tubes containing "culture medium," which is special fluid developed to support development of the embryos made to resemble that found in the fallopian tube or uterus. The dishes containing the embryos are then placed into incubators, which control the temperature and atmospheric gasses the embryos experience.

A few hours after eggs are retrieved, sperm are placed in the culture medium with the eggs, or individual sperm are injected into each mature egg in a technique called intracytoplasmic sperm injection (ICSI).

The ICSI technique has been developed to treat cases of severe male factor infertility. The ICSI technique attempts to achieve fertilization by the injection of a single sperm into the cytoplasm (interior) of the egg. Mature eggs are freed of surrounding cells by a combination of enzyme treatment and microdissection. Using special micromanipulation equipment (joystick-controlled robotics), the eggs are individually injected with a single sperm. Injected eggs are returned to the laboratory incubator and are treated as in conventional IVF-ET.  

The eggs are then returned to the incubator, where they remain to develop. Periodically, over the next few days, the dishes are inspected so the development of the embryos can be assessed.

The following day after eggs have been inseminated or injected with a single sperm (ICSI), they are examined for signs that the process of fertilization is underway. At this stage, normal development is evident by the still single cell having two nuclei; this stage is called a zygote. Two days after insemination or ICSI, normal embryos have divided into about four cells. Three days after insemination or ICSI, normally developing embryos contain about eight cells. Five days after insemination or ICSI, normally developing embryos have developed to the blastocyst stage, which is typified by an embryo that now has 80 or more cells, an inner fluid-filled cavity, and a small cluster of cells called the inner cell mass.

It is important to note that since many eggs and embryos are abnormal, it is expected that not all eggs will fertilize and not all embryos will divide at a normal rate. The chance that a developing embryo will produce a pregnancy is related to whether its development in the lab is normal, but this correlation is not perfect. This means that not all embryos developing at the normal rate are in fact also genetically normal, and not all poorly developing embryos are genetically abnormal. Nonetheless, their visual appearance is the most common and useful guide in the selection of the best embryo(s) for transfer.

In spite of reasonable precautions, any of the following may occur in the lab that would prevent the establishment of a pregnancy:

• Fertilization of the egg(s) may fail to occur.
• One or more eggs may be fertilized abnormally, resulting in an abnormal number of chromosomes in the embryo; these abnormal embryos will not be transferred.
• The fertilized eggs may degenerate before dividing into embryos, or adequate embryonic development may fail to occur.
• Bacterial contamination or a laboratory accident may result in loss or damage to some or all of the eggs or embryos.
• Laboratory equipment may fail, and/or extended power losses can occur which could lead to the destruction of eggs, sperm and embryos.
• Other unforeseen circumstances may prevent any step of the procedure to be performed or prevent the establishment of a pregnancy.

Embryos are often transferred to the uterus three to six days after retrieval. Sometimes assisted hatching is used on day 3 embryos, which may consist of six to eight cells. After transfer of a day 3 embryo, the embryo must continue to develop to the blastocyst stage (a hollow ball of about 100 cells) before implantation can occur. This development takes several days. Immediately before implantation, the blastocyst must "'hatch" from the zona coating which originally enveloped the egg. To assist the hatching process, a hole is made into the sac (zona pellucida) that surrounds the developing embryos just prior to embryo transfer. This involves dissolving part of the zona coating with an acid solution or cutting it with a fine needle or laser. Trained personnel, using specialized micromanipulation tools, must perform this under the microscope. There is a small risk of damage to the embryos from the procedure. 

Preimplantation Genetic Diagnosis (PGD) and Preimplantation Genetic Screening (PGS) are two techniques that can be used during in vitro fertilization (IVF) procedures to test embryos for genetic disorders prior to their transfer to the uterus. PGD and PGS make it possible for couples or individuals with serious inherited disorders to decrease the risk of having a child who is affected by the same problem. Both of these techniques involve the use of the micromanipulator to remove a cell from an embryo. This cell is then sent to a diagnostic lab to determine the embryo’s normalcy. Acceptable embryos can then be transferred into the patient, decreasing her odds of having an affected child. PGS has also been reported to increase the pregnancy rates of some women with chromosomal disorders that result in either lower implantation rates of embryos or higher miscarriage rates. 

Step 8 - Embryo Transfer 

• After a few days of development, the best appearing embryos are selected for transfer.
• The number chosen influences the pregnancy rate and the multiple pregnancy rate.
• A woman’s age and the appearance of the developing embryo have the greatest influences on pregnancy outcome.
• Embryos are placed in the uterine cavity with a thin tube.
• Excess embryos of sufficient quality that are not transferred can be frozen.

 The embryo transfer procedure is usually performed three to five days after oocyte retrieval. The physician will pass a catheter gently through the cervix into the uterus and deposit the embryos into the uterine cavity along with an extremely small amount of fluid. This procedure usually does not require anesthesia, and the patient usually leaves the office after a brief recovery period. SART has specific guidelines on the number of embryos to transfer – see below. Remaining embryos can be frozen for a future frozen embryo transfer cycle.

Step 9 - Cryopreservation of Embryos

Step 10 – Hormonal Support of the Uterine Lining (Progesterone Supplements) 

• Successful attachment of embryo(s) to the uterine lining depends on adequate hormonal support.
• Progesterone, given by the intramuscular or vaginal route, is routinely given for this purpose.

Progesterone supplementation can occur using vaginal, oral or injectable progestreone, and in some cases, a combination of methods. Supplementation usually begins on the day of or the day after oocyte retrieval. Usually, cells in the follicle will produce progesterone following aspiration. During oocyte retrieval, some of these cells may be removed along with the oocyte. Supplemental progesterone helps prepare the uterine lining for implantation.

This daily medication will continue until your pregnancy test. If the test is positive, you may be advised to continue to take progesterone for several more weeks.

Step 11 - Pregnancy Test

A pregnancy test is necessary regardless of vaginal spotting or bleeding.  It determines if pregnancy has occurred and is done 9-12 days after the embryo transfer. This test is usually repeated 2 days later if positive. If the test is negative, the doctor may instruct you to stop the progesterone.

Step 12 - Early Pregnancy Follow-up

Close scrutiny of a pregnancy is necessary to try to identify miscarriages or ectopic pregnancies and to help counsel regarding the status and treatment of multiple gestations. Patients are generally released to their obstetrician at 8-10 weeks gestation. 

‹ Go back to Patient's Guide Index      |      Go to Next Topic ›